Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

ARCH × Φ: Sterols and the evolution of gated biological execution.

Bio Systems·2026

Same author

A Non-Classical Neuroactive Steroid Exhibiting Potent, Efficacious GABA<sub>A</sub> Receptor Agonism and NMDA Receptor Inhibition.

bioRxiv : the preprint server for biology·2026

Same author

Structure-activity relationships of steroid and sterol neuromodulators on inflammatory markers in a murine microglial cell line.

The Journal of steroid biochemistry and molecular biology·2026

Same author

Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report.

The international journal of neuropsychopharmacology·2026

Same author

Rapid antidepressant potential of nitrous oxide: current state and major questions.

Molecular psychiatry·2025

Same author

An Exploratory Study of Machine Learning-Based Open-Angle Glaucoma Detection Using Specific Autoantibodies.

Biomedicines·2025

Search research articles

Related Experiment Video

Updated: Nov 30, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical

Eric J Lenze¹, Caline Mattar², Charles F Zorumski¹

¹Department of Psychiatry, School of Medicine, Washington University in St Louis, St Louis, Missouri.

|November 12, 2020

Summary

This summary is machine-generated.

Fluvoxamine may reduce clinical deterioration in patients with mild Coronavirus disease 2019 (COVID-19). This study found a lower likelihood of deterioration in patients treated with fluvoxamine compared to placebo.

More Related Videos

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

Related Experiment Videos

Last Updated: Nov 30, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

Area of Science:

Infectious Diseases
Pharmacology
Critical Care Medicine

Background:

Coronavirus disease 2019 (COVID-19) can cause severe illness due to an overactive immune response.
Fluvuvoxamine, a selective serotonin reuptake inhibitor, may modulate the immune response by stimulating the sigma-1 receptor, potentially regulating cytokine production.

Purpose of the Study:

To investigate the efficacy of fluvoxamine in preventing clinical deterioration in non-hospitalized adults with mild COVID-19.
To assess whether early treatment with fluvoxamine reduces disease severity.

Main Methods:

A double-blind, randomized, placebo-controlled trial was conducted remotely.
152 participants with confirmed SARS-CoV-2 infection and symptom onset within 7 days were enrolled.
Participants received either fluvoxamine (100 mg three times daily) or placebo for 15 days.

Main Results:

Clinical deterioration occurred in 0 out of 80 patients receiving fluvoxamine versus 6 out of 72 patients receiving placebo within 15 days.
The difference in clinical deterioration was statistically significant (log-rank P = .009).
Fewer serious adverse events were reported in the fluvoxamine group compared to the placebo group.

Conclusions:

Fluvoxamine treatment was associated with a reduced likelihood of clinical deterioration in outpatients with symptomatic COVID-19.
The study suggests a potential role for fluvoxamine in managing mild COVID-19.
Larger trials with longer follow-up are needed to confirm clinical efficacy and definitive outcomes.